{
  "ticker": "RVMD",
  "company_name": "Revolution Medicines, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC",
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT05054725",
      "title": "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Non-Small Cell Lung Cancer",
      "start_date": "2021-12-30",
      "completion_date": "2024-08-29",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT04418661",
      "title": "Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Metastatic Neoplasm",
      "start_date": "2020-06-09",
      "completion_date": "2024-04-04",
      "enrollment": 0,
      "sponsor": "Sanofi"
    },
    {
      "nct_id": "NCT06128551",
      "title": "Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma",
      "start_date": "2023-11-14",
      "completion_date": "2026-11-30",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT04774952",
      "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Tumors",
      "start_date": "2021-04-07",
      "completion_date": "2024-06-28",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT03634982",
      "title": "Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "Solid Tumors",
      "start_date": "2018-09-28",
      "completion_date": "2023-05-31",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT06922591",
      "title": "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer",
      "start_date": "2025-05-31",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Tango Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06881784",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)",
      "start_date": "2025-05-06",
      "completion_date": "2030-12-01",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT07252232",
      "title": "Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma",
      "start_date": "2025-12-15",
      "completion_date": "2030-07-10",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    },
    {
      "nct_id": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor",
      "start_date": "2019-07-02",
      "completion_date": "2022-02-08",
      "enrollment": 0,
      "sponsor": "Revolution Medicines, Inc."
    }
  ],
  "summary": {
    "total_trials": 17,
    "by_phase": {
      "PHASE1, PHASE2": 6,
      "PHASE2": 1,
      "PHASE1": 7,
      "PHASE3": 3
    },
    "by_status": {
      "RECRUITING": 10,
      "COMPLETED": 3,
      "TERMINATED": 1,
      "UNKNOWN": 1,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 12,
    "completed_trials": 3,
    "conditions": [
      "Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
      "Glioblastoma, Recurrent Glioblastoma",
      "Metastatic Neoplasm",
      "NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)",
      "Non-Small Cell Lung Cancer",
      "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor",
      "Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma",
      "Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC",
      "Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors",
      "Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors",
      "PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer",
      "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma",
      "Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma",
      "Solid Tumor",
      "Solid Tumors"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:41.044827",
    "search_query": "Revolution Medicines, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Revolution+Medicines,+Inc."
  }
}